The unique subset of ALK-positive ALCL patients additionally presents with the potential for targeted therapeutics involving small molecule inhibitors against ALK, such as crizotinib, ceritinib and alectinib. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.